1. Home
  2. JMIA vs SPRY Comparison

JMIA vs SPRY Comparison

Compare JMIA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jumia Technologies AG each representing two

JMIA

Jumia Technologies AG each representing two

HOLD

Current Price

$7.07

Market Cap

862.0M

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$7.45

Market Cap

823.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JMIA
SPRY
Founded
2012
2015
Country
Germany
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
862.0M
823.2M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
JMIA
SPRY
Price
$7.07
$7.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$16.75
$40.00
AVG Volume (30 Days)
3.1M
1.7M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$84,278,000.00
Revenue This Year
$22.18
$87.40
Revenue Next Year
$23.26
$81.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.89
$6.66
52 Week High
$14.72
$18.63

Technical Indicators

Market Signals
Indicator
JMIA
SPRY
Relative Strength Index (RSI) 45.98 35.06
Support Level $6.70 $6.66
Resistance Level $9.49 $8.61
Average True Range (ATR) 0.50 0.52
MACD 0.01 -0.10
Stochastic Oscillator 14.50 14.57

Price Performance

Historical Comparison
JMIA
SPRY

About JMIA Jumia Technologies AG each representing two

Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: